Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial - Bidard, F-C; Kaklamani, V G; Neven, P (J Clin Oncol, 2022)
et al.